Topotecan–carboplatin–etoposide combination as 1st line treatment in patients with small cell lung cancer

Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

Kazumasa Noda, Yutaka Nishiwaki, Masaaki Kawahara et al. · New England Journal of Medicine · 2002 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +12

A phase II study

Philippe Rougier, Antoine Adenis, Michel Ducreux et al. · European Journal of Cancer · 2000 · 752 citations

Public Health, Biostatistics, Experimental Design +4

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

Andrea Ardizzoni, H. Hansen, P Dombernowsky et al. · Journal of Clinical Oncology · 1997 · 481 citations

Medicine, Oncology, Pharmacology +14

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.

M L Slevin, Peter Clark, S P Joel et al. · Journal of Clinical Oncology · 1989 · 464 citations

Medicine, Oncology, Pharmacology +14

Topotecan Versus Observation After Cisplatin Plus Etoposide in Extensive-Stage Small-Cell Lung Cancer: E7593—A Phase III Trial of the Eastern Cooperative Oncology Group

Joan H. Schiller, Sudeshna Adak, David Cella et al. · Journal of Clinical Oncology · 2001 · 294 citations

Medicine, Oncology, Pharmacology +15